-+ 0.00%
-+ 0.00%
-+ 0.00%

MediciNova Reveals That As Of The End Of January 2026, 12 Sites In The US Are Activated And 100 Patients Have Been Enrolled In The SEANOBI Study

Benzinga·01/29/2026 23:03:36
Listen to the news

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that as of the end of January 2026, 12 sites in the US are activated and 100 patients have been enrolled in the SEANOBI study (Scalable Expanded Access with Analysis of Neurofilament and Other Biomarkers in ALS; NCT 06743776) representing 50% of the planned 200-enrollment, evaluating MN‑166 (ibudilast) in patients with amyotrophic lateral sclerosis (ALS).